|
|
Article: Amicus Therapeutics Appoints David J. Lockhart Chief Scientific Officer.
- Article from:
- PR Newswire
- Article date:
- January 6, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Dr. Lockhart Will Lead the Research Organization and Oversee the Advancement of Amicus' Pharmacological Chaperone Technology
CRANBURY, N.J., Jan. 6 /PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-active pharmacological chaperones for the treatment of human genetic diseases, today announced that David J. Lockhart, Ph.D. has been appointed chief scientific officer. Dr. Lockhart most recently served as president and chief scientific officer of Ambit Biosciences in San Diego following leadership positions at the Genomics Institute of the Novartis Research Foundation and Affymetrix where he was the primary developer ...